Novo Nordisk Seeks Injunction to Block Eli Lilly Weight-Loss Drug Ads
Novo Nordisk has filed a request with a U.S. court for an emergency injunction aimed at halting advertisements by Eli Lilly that compare their obesity and diabetes treatments, which Novo claims are misleading. This legal move escalates the ongoing dispute between two leading pharmaceutical companies competing in the fast-growing weight-loss drug market. The lawsuit highlights intensifying competition as both firms vie to lead a sector projected to surpass $100 billion by 2030. Eli Lilly has denied any wrongdoing and stated it will defend its advertising practices, though no further comment was provided on Friday. The case is expected to proceed through the courts. The outcome could influence consumer perception of both companies' products and potentially impact their market positions in a sector experiencing strong global demand for next-generation obesity treatments.